As of June 21, 2025, Clovis Oncology Inc (CLVS) reports a Gross Margin of 73.90%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Clovis Oncology Inc's Gross Margin
Over recent years, Clovis Oncology Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2021-12-31 | 73.90% |
| 2020-12-31 | 74.89% |
| 2019-12-31 | 75.73% |
| 2018-12-31 | 76.83% |
| 2017-12-31 | 78.92% |
This gradual decrease highlights how Clovis Oncology Inc manages its operational efficiency and pricing power over time.
Comparing Clovis Oncology Inc's Gross Margin to Peers
To better understand Clovis Oncology Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Clovis Oncology Inc (CLVS) | 73.90% |
| CytomX Therapeutics Inc (CTMX) | 7775.20% |
| Merus NV (MRUS) | 7775.20% |
| Surface Oncology Inc (SURF) | 7775.20% |
| Chinook Therapeutics Inc (KDNY) | 7775.20% |
| Sigilon Therapeutics Inc (SGTX) | 7775.20% |
Compared to its competitors, Clovis Oncology Inc's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.